#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alternating hemiplegia of childhood Alveolar proteinosis Haemophilia Dementia with Lewy bodies Waldenstrom's macroglobulinaemia Cardiac sarcoidosis Essential thrombocythaemia Hereditary neuropathic amyloidosis Hereditary motor and sensory neuropathy Ichthyosis Renal disorder Fragile X syndrome Solitary fibrous tumour Osteosarcoma metastatic VEXAS syndrome More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma – Treatment Alport’s syndrome – Diagnostics Waldenstrom’s macroglobulinaemia refractory – Basic Information Lymphangioma – Treatment Soft tissue sarcoma – Life with Disease Hepatoblastoma – Trials in Disease Osteosarcoma recurrent – Life with Disease Testicular leiomyosarcoma Familial amyotrophic lateral sclerosis – Treatment Tuberous sclerosis complex – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ZILEBESIRAN Alendronic Acid Paeonol Placebo Dapagliflozin Propanediol Kbp-336 Nedosiran SPY002 Maridebart Cafraglutide Amcenestrant Pentixafor Gallium Ga-68 IG-TREGS Belzupacap Sarotalocan BMS-986365 REGN7544 HUMAN COAGULATION FACTOR XIII Gliclazide Quc398 Oxazepam Thiamine Nitrate More therapies…

    Learn about Your Condition

    Endometrial cancer stage II Retinoblastoma Hyperchylomicronaemia Anal squamous cell carcinoma Polymyalgia rheumatica Dry mouth Thrombotic microangiopathy Ocular myasthenia Aortic stenosis Spina bifida Angiopathy Mitochondrial DNA depletion Hysterectomy Anal fissure Torticollis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    • Povorcitinib
    Austria Belgium Bulgaria Czechia Denmark France +7
  • Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

    Recruiting

    3 1 1
    Investigated Drugs:
    • Pelacarsen
    Austria Belgium Bulgaria Czechia Denmark France +14
  • Study of GHZ339 for treatment of moderate to severe atopic dermatitis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Pimecrolimus
    • Tacrolimus
    Czechia France Germany Hungary Italy The Netherlands +3
  • Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Human Normal Immunoglobulin
    • Teclistamab
    Austria Czechia Denmark Germany Greece Hungary +6
  • Comparison of Low-Dose Exemestane versus Low-Dose Tamoxifen for Breast Cancer Prevention in Postmenopausal Women at High Risk

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Tamoxifen Citrate
    • Exemestane
    Italy Portugal
  • Study of Etranacogene Dezaparvovec (CSL222) in Adolescent Males with Severe or Moderately Severe Hemophilia B

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Etranacogene Dezaparvovec
    Austria Belgium France Spain
Previous Page
1 … 646 647 648 649 650 … 1,655
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.


European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!